메뉴 건너뛰기




Volumn 72, Issue 2, 2013, Pages 241-244

Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

EID: 84872088361     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202297     Document Type: Article
Times cited : (48)

References (22)
  • 1
    • 77950238310 scopus 로고    scopus 로고
    • Autoantibodies in rheumatoid arthritis: Rheumatoid factors and anticitrullinated protein antibodies
    • Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010;103:139-46.
    • (2010) QJM , vol.103 , pp. 139-146
    • Song, Y.W.1    Kang, E.H.2
  • 2
    • 7044279878 scopus 로고    scopus 로고
    • Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations
    • De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
    • (2004) Ann Rheum Dis , vol.63 , pp. 1587-1593
    • De Rycke, L.1    Peene, I.2    Hoffman, I.E.3
  • 3
    • 33645116507 scopus 로고    scopus 로고
    • Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset
    • Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
    • (2006) Ann Rheum Dis , vol.65 , pp. 453-458
    • Berglin, E.1    Johansson, T.2    Sundin, U.3
  • 4
    • 34447316727 scopus 로고    scopus 로고
    • Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis
    • Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 2007;100:193-201.
    • (2007) QJM , vol.100 , pp. 193-201
    • Niewold, T.B.1    Harrison, M.J.2    Paget, S.A.3
  • 5
    • 77956036473 scopus 로고    scopus 로고
    • 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
    • Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1580-1588
    • Aletaha, D.1    Neogi, T.2    Silman, A.J.3
  • 6
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
    • (2010) Ann Rheum Dis , vol.69 , pp. 964-975
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3
  • 7
    • 34848842839 scopus 로고    scopus 로고
    • Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients
    • Bobbio-Pallavicini F, Caporali R, Alpini C, et al. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 2007;1109:287-95.
    • (2007) Ann N y Acad Sci , vol.1109 , pp. 287-295
    • Bobbio-Pallavicini, F.1    Caporali, R.2    Alpini, C.3
  • 8
    • 34147220774 scopus 로고    scopus 로고
    • High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis
    • Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.
    • (2007) Ann Rheum Dis , vol.66 , pp. 302-307
    • Bobbio-Pallavicini, F.1    Caporali, R.2    Alpini, C.3
  • 9
    • 1942440157 scopus 로고    scopus 로고
    • Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
    • Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
    • (2004) Ann Rheum Dis , vol.63 , pp. 1218-1221
    • Alessandri, C.1    Bombardieri, M.2    Papa, N.3
  • 10
    • 77950307115 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis to target: Recommendations of an international task force
    • Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
    • (2010) Ann Rheum Dis , vol.69 , pp. 631-637
    • Smolen, J.S.1    Aletaha, D.2    Bijlsma, J.W.3
  • 11
    • 36448970927 scopus 로고    scopus 로고
    • The use of databases for quality assessment in rheumatoid arthritis
    • Stamm TA, Aletaha D, Pflugbeil S, et al. The use of databases for quality assessment in rheumatoid arthritis. Clin Exp Rheumatol 2007;25:82-5.
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 82-85
    • Stamm, T.A.1    Aletaha, D.2    Pflugbeil, S.3
  • 12
    • 0023945481 scopus 로고
    • The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
    • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
    • (1988) Arthritis Rheum , vol.31 , pp. 315-324
    • Arnett, F.C.1    Edworthy, S.M.2    Bloch, D.A.3
  • 13
    • 0344127554 scopus 로고    scopus 로고
    • A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    • Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57.
    • (2003) Rheumatology (Oxford) , vol.42 , pp. 244-257
    • Smolen, J.S.1    Breedveld, F.C.2    Schiff, M.H.3
  • 14
    • 84862560815 scopus 로고    scopus 로고
    • Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
    • Aletaha D, Martinez-Avila J, Kvien TK, et al. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012.
    • (2012) Ann Rheum Dis
    • Aletaha, D.1    Martinez-Avila, J.2    Kvien, T.K.3
  • 15
    • 67349090358 scopus 로고    scopus 로고
    • Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study
    • Atzeni F, Sarzi-Puttini P, Dell' Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006;8:R30.
    • (2006) Arthritis Res Ther , vol.8
    • Atzeni, F.1    Sarzi-Puttini, P.2    Dell'Acqua, D.3
  • 16
    • 29144519684 scopus 로고    scopus 로고
    • The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
    • Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:35-9.
    • (2006) Ann Rheum Dis , vol.65 , pp. 35-39
    • Chen, H.A.1    Lin, K.C.2    Chen, C.H.3
  • 17
    • 13244261140 scopus 로고    scopus 로고
    • Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
    • De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302.
    • (2005) Ann Rheum Dis , vol.64 , pp. 299-302
    • De Rycke, L.1    Verhelst, X.2    Kruithof, E.3
  • 18
    • 66449092062 scopus 로고    scopus 로고
    • Enhanced reactivity to pain in patients with rheumatoid arthritis
    • Edwards RR, Wasan AD, Bingham CO 3rd, et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther 2009;11:R61.
    • (2009) Arthritis Res Ther , vol.11
    • Edwards, R.R.1    Wasan, A.D.2    Bingham III, C.O.3
  • 19
    • 84859449924 scopus 로고    scopus 로고
    • The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis
    • Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011;2011:765624.
    • (2011) Arthritis , vol.2011 , pp. 765624
    • Hashizume, M.1    Mihara, M.2
  • 20
    • 0036166461 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis early: A window of opportunity?
    • O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
    • (2002) Arthritis Rheum , vol.46 , pp. 283-285
    • O'Dell, J.R.1
  • 21
    • 10444250299 scopus 로고    scopus 로고
    • Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody
    • Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.
    • (2004) Arthritis Rheum , vol.50 , pp. 3776-3782
    • Mikuls, T.R.1    O'Dell, J.R.2    Stoner, J.A.3
  • 22
    • 79957647039 scopus 로고    scopus 로고
    • Predictors of radiographic progression in the ESPOIR cohort: The season of first symptoms may influence the short-term outcome in early arthritis
    • Mouterde G, Lukas C, Logeart I, et al. Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011;70:1251-6.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1251-1256
    • Mouterde, G.1    Lukas, C.2    Logeart, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.